Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4552W HIGH $38.33
Volume
339.52 K
Value Traded
6.44 M
Short % Float
10.71%
Days to Cover
11.2
+1.08%Week
+6.28%1 Month
-24.75%3 Month
-17.12%6 Month
-79.88%5 Year
-93.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.33 B
EPS (TTM)
-4.26
P/E Ratio
-
Ent. Value
786.18 M
Total Shares
61.73 M
Float Shares
48.12 M
Insiders
22.08%
Institutions
88.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
DMRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Damora Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Damora Therapeutics, Inc.
72Total events
10Upcoming
16Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationDMR-001Trial
Initiated Phase 1/1b CLARITY-101 trial of DMR-001
mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF)source ↗
▲Trial InitiationDMR-001Trial
Initiation of Phase 1/1b CLARITY-101 trial of DMR-001
mutant calreticulin-driven essential thrombocythemia and myelofibrosissource ↗
●IND SubmissionDMR-001IND
IND submission for DMR-001 expected in mid-2026
mutant calreticulin-driven Myeloproliferative Neoplasms (ET and MF)source ↗
▲First Patient DosedDMR-001Trial
First-in-human administration of DMR-001 anticipated in mid-2026
mutant calreticulin-driven Myeloproliferative Neoplasms (ET and MF)source ↗
●Oral PresentationDMR-001Presentation
Presented DMR-001 preclinical data at EHA 2026 Congress
mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF)source ↗
◆Management ChangeCorporate
Jennifer Jarrett appointed President and CEO, effective March 30, 2026
◆Management ChangeCorporate
Cameron Turtle and Mike Landsittel appointed to Board of Directors
●IND SubmissionGB3226IND
IND application for GB3226 planned in Q1 2026
acute myeloid leukemia (AML)source ↗
▲Oral PresentationDMR-001Presentation
Preclinical DMR-001 data presented at EHA 2026 Congress
mutant calreticulin-driven essential thrombocythemia and myelofibrosissource ↗
●Poster PresentationGB3226Presentation
Two poster presentations on GB3226 at 67th ASH Annual Meeting
acute myeloid leukemia (AML)source ↗
▼Equity OfferingCorporate
Concurrent oversubscribed $284.9 million private placement of Series C convertible preferred stock
▲FDA Feedback ReceivedGB3226FDA Meeting
Constructive FDA feedback on pre-IND submission for GB3226
acute myeloid leukemia (AML)source ↗
●Quarterly UpdateCorporate
Webcast to discuss transaction and pipeline on November 10, 2025 at 8:00 a.m. ET
●Trial InitiationGB1211Trial
Investigator-initiated Phase 2 trial of GB1211 in combination with pembrolizumab expected to start
non-small cell lung cancersource ↗
▲Poster PresentationGB1211Presentation
Poster presentation of updated clinical data from Part A of GALLANT-1 trial at ESMO Congress 2023
advanced non-small cell lung cancersource ↗
▼Trial DiscontinuedGB1211Trial
Galecto will not initiate Part B of GALLANT-1 trial
advanced non-small cell lung cancersource ↗
◆Timing GuidancePresentation
Plan to provide greater detail and next steps for liver disease pipeline before end of October 2023
▼Topline ReadoutGB0139Clinical Data
Topline results from Phase 2b GALACTIC-1 trial of GB0139 for IPF
idiopathic pulmonary fibrosissource ↗
▼Program DiscontinuationGB0139Corporate
Discontinuation of GB0139 development for IPF
idiopathic pulmonary fibrosissource ↗
◆Topline ReadoutGB2064Clinical Data
Topline data from Phase 2a MYLOX-1 trial of GB2064 in myelofibrosis expected in 2H 2023
Myelofibrosissource ↗
◆Topline ReadoutGB0139Clinical Data
Topline data from Phase 2b GALACTIC-1 trial of GB0139 in IPF expected mid-2023
Idiopathic Pulmonary Fibrosissource ↗
◆Enrollment CompleteGB1211Trial
Complete Phase 2a enrollment for GB1211 in NSCLC expected mid-2023
Non-small cell lung cancersource ↗
◆FDA Feedback ReceivedGB1211FDA Meeting
End of study regulatory discussions for GB1211 in liver fibrosis expected in 1H 2023
Liver Fibrosissource ↗
◆Trial InitiationGB1211Trial
Trial initiation for GB1211 in melanoma and HNSCC expected in 2023
Melanoma & HNSCCsource ↗
●Type C MeetingGB1211FDA Meeting
FDA Type C meeting for GB1211 development in cirrhosis
compensated and decompensated cirrhosissource ↗
◆Oral PresentationGB1211Presentation
Preliminary safety, pharmacokinetics, and efficacy of GB1211 in cirrhotic patients: initial findings from the GULLIVER-2 trial with focus on the randomized, placebo controlled, 12-week part 2
decompensated cirrhosissource ↗
◆Quarterly UpdateCorporate
Galecto to host a webinar to discuss expanded topline data and analysis from GULLIVER-2 trial
◆Poster PresentationGB1211Presentation
The novel GALECTIN-3 inhibitor GB1211 reduces inflammation & fibrosis in a rabbit high fat diet model of NASH & fibrosis
NASH/fibrosissource ↗
◆Poster PresentationGB1211Presentation
GULLIVER-2 is an innovative, hybrid, hepatic impairment trial of the oral GALECTIN-3 inhibitor GB1211
decompensated cirrhosissource ↗
▲Topline ReadoutGB1211Clinical Data
Topline data from GULLIVER-2 Part 2 showing GB1211 reduced signs of liver impairment
decompensated cirrhosissource ↗
◆Topline ReadoutGB1211Clinical Data
Top-line results from GULLIVER-2 trial for liver cirrhosis expected in coming weeks
liver cirrhosissource ↗
▲Interim AnalysisGB2064Trial
Positive results from planned intermediate assessment of MYLOX-1 trial: 4/5 evaluable patients showed 1-grade reduction in collagen fibrosis
myelofibrosissource ↗
◆Oral PresentationGB0139Presentation
Abstract of trial results accepted for presentation at 2022 ATS Conference
COVID-19source ↗
▲Full ResultsGB0139Clinical Data
Publication of full results of investigator-initiated trial of GB0139 in hospitalized COVID-19 patients
COVID-19source ↗
◆Protocol AmendmentGB0139Trial
Plan to seek regulatory approval of protocol amendment to reduce target patient population for GALACTIC-1 trial
IPFsource ↗
Past FDA Catalysts and PDUFA Decisions
How DMRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | DMR-001 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 49%
Micro Cap(rank 331 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMR-001 Small moleculeNCT07849231 | Myeloproliferative Neoplasms (MPNs) | Phase 1 | RECRUITING | 250 | Jun 1, 2030 | ||||||
| GB2064 Small moleculeNCT04679870 | Myelofibrosis | Phase 2 | ACTIVE NOT_RECRUITING | 21 | Jun 30, 2026 | ||||||
| GB1211 Small moleculeCompletedNCT03809052 | Safety and Tolerability | Phase 1 | COMPLETED | 78 | Jun 25, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every DMRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GB1211 | advanced non-small cell lung cancer | Phase 1b/2a | 2023-10-23 | 60% partial response rate in five patientsRead More | Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jarrett JenniferDirector, Officer (Director, President and CEO) | Buy | 12,500 512,500 held | $20.23 | 09/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DMRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DMRA for Q2 2026. | ||||
Ownership Trends
DMRA Short Interest
Shares sold short, counted twice a month.
10.71%
Short % of Float
of tradable shares sold short
5.2M
Shares Sold Short
+8.9% vs prior count
11.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
461.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DMRA ranks across every disease it competes in
Competitive Position is a premium feature
See how DMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDMRA News
DMRADamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics announced the granting of equity awards to five new non-executive employees as part of their hiring process. The inducement grants, which comply with Nasdaq Listing Rule 5635(c)(4), consist of options to purchase a total of 144,400 shares at an exercise price of $21.28. This initiative aims to bolster the company's workforce as it prepares to advance its clinical programs in treating blood disorders.
Read more →DMRADamora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics reported a net loss of $31.2 million for the second quarter of 2026. The company holds $540.5 million in cash and cash equivalents as of June 30, 2026. This balance is expected to fund operations into the second half of 2029. Damora also initiated the Phase 1/1b CLARITY-101 clinical trial for its DMR-001 drug.
Read more →DMRADamora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
Damora Therapeutics has launched the Phase 1/1b CLARITY-101 clinical trial for DMR-001, a monoclonal antibody aimed at treating patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis. The trial will assess the safety and efficacy of DMR-001, which has shown promising preclinical results, including high potency and a long half-life. Initial data from the trial is expected in mid-2027.
Read more →DMRADamora Announces Redomestication from Delaware to Cayman Islands
Damora Therapeutics has completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026. This transition involved the automatic conversion of shares without altering the company's business structure or obligations. The ordinary shares will continue trading on Nasdaq under the symbol DMRA, with a new CUSIP effective July 20, 2026.
Read more →DMRADamora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics reported strong first-quarter results for 2026, highlighting significant progress in its mutCALR-targeted therapy pipeline. The company is on track to submit regulatory filings for its lead programs, DMR-001 and DMR-002, in mid-2026. Despite a net loss of $27.8 million, Damora maintains a robust cash position, expected to fund operations into 2029.
Read more →DMRA▲ +27.1%on this news· ran to +41% by day 3
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Damora Therapeutics has appointed Jennifer Jarrett as President and CEO, effective March 30, 2026. With nearly three decades of experience in biotech, she is expected to drive the company’s efforts in developing therapies for blood disorders, specifically mutant calreticulin-driven myeloproliferative neoplasm. Alongside her, two new board members, Cameron Turtle and Mike Landsittel, bring significant industry expertise, strengthening Damora's leadership as it seeks to advance its pipeline of potential therapies.
Read more →DMRAGalecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
Galecto, Inc. has renamed itself Damora Therapeutics and will trade under the symbol DMRA starting March 10, 2026. The rebranding follows the acquisition of Damora and recent funding that strengthens its financial position. Damora aims to advance its therapy pipeline targeting mutCALR-driven blood disorders, with plans to submit IND applications for DMR-001 in mid-2026. The company emphasizes its focus on developing disease-modifying treatments for conditions currently lacking targeted therapies.
Read more →DMRACompany Logo Disclaimers The information contained in this presentation has been prepared by Galecto Inc. and its affiliates (“Galecto” or the “Company”) and contains information pertaining to
Galecto Inc. has acquired Damora Therapeutics, boosting its portfolio of therapies targeting mutant CALR-driven myeloproliferative neoplasms. The lead program, which is a subcutaneous anti-mutCALR monoclonal antibody, shows promise based on demonstrated clinical proof-of-concept. This acquisition positions Galecto to potentially establish a new standard of care in treating essential thrombocythemia and myelofibrosis. Galecto aims to transform treatment for patients with these conditions through innovative therapeutics.
Read more →DMRAGalecto Announces Acquisition of Damora Therapeutics
Galecto, Inc. has completed the acquisition of Damora Therapeutics, enhancing its portfolio of therapies targeting mutant calreticulin-driven Myeloproliferative Neoplasms (MPNs). The acquisition is supported by an oversubscribed private investment of approximately $285 million, which will enable Galecto to advance clinical programs, including the lead candidate DMR-001 expected to enter Phase 1 trials with proof-of-concept data anticipated in 2027. This strategic merger aims to improve treatment outcomes for patients suffering from MPNs, including Essential Thrombocythemia and Myelofibrosis.
Read more →DMRAGalecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler BOSTON
Galecto, Inc. announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler, a board-certified dermatologist and psychiatrist, brings significant industry experience and a successful record in supporting companies through critical growth phases. She is expected to provide strategic insights for the development of Galecto’s oncology pipeline. With a background in health management and clinical practice, her addition is viewed as a positive step for the company.
Read more →DMRAUNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On
On October 7, 2024, DMRA completed the Closing of an Asset Purchase, with unaudited pro forma financial statements provided to illustrate potential adjustments. These financials suggest how the transaction might have impacted historical figures had it occurred earlier. However, the information is for informational purposes only and does not guarantee future results. The company also executed a reverse stock split at a ratio of 1-for-25, impacting the historical data used in these pro forma statements.
Read more →DMRAGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211
Galecto, Inc. presented updated clinical data at the ESMO Congress 2023 related to its Phase 1b/2a GALLANT-1 trial of GB1211 combined with atezolizumab for treating advanced non-small cell lung cancer. The trial showed a 60% partial response rate in five patients, suggesting the combination may enhance treatment efficacy compared to atezolizumab alone. However, severe reactions at higher doses led to a dose reduction, and the company has decided not to proceed with Part B of the GALLANT-1 trial, opting to refocus on severe liver diseases. Galecto plans to initiate a new Phase 2 trial in early 2024 and seek external partnerships for oncology activities.
Read more →DMRAGalecto Announces Plans to Explore Strategic Alternatives Boston, MA
Galecto, Inc. has announced plans to explore strategic alternatives aimed at maximizing shareholder value, following a review of its business status. This process may involve various actions such as acquisitions, mergers, or asset divestitures, though no specific outcomes are guaranteed. Notably, the company plans to reduce its workforce by about 70% as part of a restructuring plan. As of mid-2023, Galecto reported a cash balance of $52.1 million, indicating some financial stability while it navigates this process.
Read more →DMRAGalecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis Announces next steps for clinical development plan in severe liver diseases Boston, MA
Galecto, Inc. announced topline results from its Phase 2b GALACTIC-1 trial for GB0139 in treating idiopathic pulmonary fibrosis, which did not meet its primary efficacy endpoint. Consequently, Galecto will cease development of GB0139 and shift focus to severe liver diseases with their oral candidate, GB1211. The company plans to initiate a Phase 2a trial for GB1211 targeting decompensated cirrhosis early in 2024, pending financing. Despite the setback with GB0139, past trials for GB1211 suggest positive clinical outcomes.
Read more →About Damora Therapeutics, Inc.
Headquarters221 CRESCENT STREET, WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next DMRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime